戻る Agenda
[V6-S2] Think about the Exit Strategy in Drug Discovery Processes of Academia
Session Chair(s)
Kotone Matsuyama, RPH
Center for Clinical Research and Development, National Center for Child Health and Development, Japan
In recent years, industry-academia collaboration has progressed in the field of drug / medical device development, and worldwide innovative new drug / treatment method from domestic academia has become a reality. When Academia conducts drug discovery research, it is important that both company and academia collaborate with early stages of development, because it will be manufactured and sold by a company, finally. However, academia researchers are not professionals of development, and there are cases where it is difficult to negotiate before cooperation. In this session, we will clarify the “gap between what each other wishes and what is required”, and also based on actual examples overcoming this, we will discuss the ideal way of cooperation approaches of industry, government, academia from their respective perspectives.
Speaker(s)
Hisashi Koike, PHD
Review Director, Office of New Drug IV, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Role of PMDA for Drug Development
Hiroshi Hayashi, MS
Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Japan
Actual Developmental Strategy for Regenerative Medicine Products
Tetsuji Sanuki, MD, PHD
Associate Professor, Graduate School of Medical Sciences, Nagoya City University, Japan
First SAKIGAKE Designated Medical Device to Treat Adductor Spasmodic Dysphonia
Yuki Otsuka
Clinical Research Innovation and Education Center Tohoku University Hospital, Tohoku University Hospital, Japan
Shinichi Torii
, Biogen Japan Ltd., Japan